AUPH vs. LEGN, TGTX, PCVX, MTSR, KRYS, PTCT, ARWR, ACLX, KYMR, and PTGX
Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include Legend Biotech (LEGN), TG Therapeutics (TGTX), Vaxcyte (PCVX), Metsera (MTSR), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Kymera Therapeutics (KYMR), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.
Aurinia Pharmaceuticals vs. Its Competitors
Aurinia Pharmaceuticals (NASDAQ:AUPH) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Aurinia Pharmaceuticals has a net margin of 23.31% compared to Legend Biotech's net margin of -40.83%. Aurinia Pharmaceuticals' return on equity of 20.06% beat Legend Biotech's return on equity.
In the previous week, Legend Biotech had 9 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 14 mentions for Legend Biotech and 5 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.51 beat Legend Biotech's score of 0.43 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.
Aurinia Pharmaceuticals has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.
Aurinia Pharmaceuticals presently has a consensus price target of $13.00, suggesting a potential upside of 13.34%. Legend Biotech has a consensus price target of $69.25, suggesting a potential upside of 105.37%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Aurinia Pharmaceuticals beats Legend Biotech on 9 of the 16 factors compared between the two stocks.
Get Aurinia Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurinia Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AUPH) was last updated on 10/15/2025 by MarketBeat.com Staff
